Abstract
BACKGROUND: Allisartan isoproxil is a selective nonpeptide angiotensin II (AT1) receptor blocker developed by China, this study aimed to assess its cl......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
